A phase II study to assess the efficacy and safety of frontline combination of dasatinib (SPRYCEL�) and pegylated-interferon alpha 2b (Peg-IFN?2b) therapy in patients newly diagnosed with chronic phase chronic myeloid leukaemia (CP-CML)

The primary objective of this study is to assess the efficacy of dasatinib combined to Peg-interferon-?2b on the cumulative rate of molecular response 4.5 (MR4.5) at 12 months, as frontline therapy for newly diagnosed CP-CML patients.